IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis https://www.accessnewswire.com/news...ma-trial-advances-toward-completion-a-1172698
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses https://www.accessnewswire.com/news...ent-enrollment-target-in-phase-2-calm-1175965
$IGC IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
$IGC IGC Pharma, Inc. (NYSE: IGC), a clinical-stage biotechnology company developing Alzheimer’s disease therapeutics and AI-enabled healthcare technologies, disclosed in a Form 4 filing that two senior executives increased their ownership stakes through debt-for-equity transactions. IGC Pharma (NYSE: IGC) CEO and CFO Acquire More Than 4.2 Million Shares
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC https://www.accessnewswire.com/news...urchase-more-than-1.15-million-of-com-1187333
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development https://www.accessnewswire.com/news...6-including-aha-platform-that-reduced-1188740
IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No. 2:24-CR-456, in the United States District Court for the Central District of California. https://www.accessnewswire.com/news...as-federal-jury-verdict-brings-renewe-1197865
IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence ("AI")-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1, the Company's lead Alzheimer's drug candidate, advances toward expected Phase 2 topline results in the fourth quarter of 2026. IGC Pharma Advances CALMA Toward Q4 Topline Readout
IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer's disease, today announced financial results for the second quarter ended June 30, 2026, and provided an update on the Company's lead Alzheimer's program, IGC-AD1. IGC Pharma Q2 Results: CALMA Nears Enrollment Closure
IGC Pharma Analyst Rating Update https://www.gurufocus.com/news/9053...ascendiant-capital-price-target-raised-to-600
